The supplementation significantly reduced participants weight, body mass index (BMI), total cholesterol, blood sugar, insulin, and systolic blood pressure
Dose-by-dose weight loss in Phase 2 (NEJM) Phase 2 NEJM weight loss by dose, 24 and 48 weeks Dose 1 mg 24 weeks -7.2% 48 weeks -8.7% Dose 4 mg 24 weeks -12.9% 48 weeks -17.5% Dose 8 mg 24 weeks -15.7% 48 weeks -22.8% Dose 12 mg 24 weeks -17.5% 48 weeks -24.2% Dose Placebo 24 weeks -1.6% 48 weeks -2.1% Source: Jastreboff et al., NEJM 2023
There is no natural third GLP peptide in the human body
benefits of GLP-1RAs for your specific situation
57 However, subsequent evidence from large RCTs and real-world studies has not consistently confirmed a causal association between GLP-1 RA use and pancreatitis
GLP1 Drugs (Wegovy, Zepbound): Pros: Highly effective, non-invasive, strong appetite suppression, rapid results